# ‚öîÔ∏è CLINICAL TRIAL DOSSIER

**NCT ID**: NCT02351479  
**Trial Title**: Hula, a Physical Activity Intervention for Female-Cancer Survivors  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:42:27.313818  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: Hula, a Physical Activity Intervention for Female-Cancer Survivors  
**Phase**:   
**Status**: COMPLETED  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: None

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT02351479

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 4/6 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ‚úÖ PASS | 0.90 | Ovarian/gynecologic match: ["physical activity", "breast cancer", "cervical cancer", "ovarian cancer", "endometrial cancer"] |
| Treatment Line | ‚úÖ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ‚úÖ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ‚úÖ PASS | 0.50 | No location data (assume match) |
| Inclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * Lives on Oahu
* Diagnosed with primary breast,cervical, endometrial or ovarian cancer (stage I-III)
* Completed initial regional and systemic treatment for breast cancer 2 months ago
* Physically ca... |
| Exclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * Currently undergoing chemotherapy or radiation therapy... |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 66.7%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 66.7%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 66.7%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

### [

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for [

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

### "

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for "

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

### H

**Mechanism (Technical)**: Alkylating agent. Forms DNA cross-links, causing apoptosis.

**Mechanism (Layman)**: A chemotherapy drug that damages cancer cell DNA.

**Evidence Tier**: STANDARD

### u

**Mechanism (Technical)**: Anti-VEGF monoclonal antibody. Blocks vascular endothelial growth factor, inhibiting angiogenesis.

**Mechanism (Layman)**: A targeted therapy that starves tumors by cutting off their blood supply.

**Evidence Tier**: SUPPORTED

### l

**Mechanism (Technical)**: Platinum-based alkylating agent. Forms DNA cross-links, causing double-strand breaks and apoptosis.

**Mechanism (Layman)**: A chemotherapy drug that damages cancer cell DNA, preventing cell division.

**Evidence Tier**: STANDARD

### a

**Mechanism (Technical)**: Platinum-based alkylating agent. Forms DNA cross-links, causing double-strand breaks and apoptosis.

**Mechanism (Layman)**: A chemotherapy drug that damages cancer cell DNA, preventing cell division.

**Evidence Tier**: STANDARD

### ]

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for ]

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

* Lives on Oahu
* Diagnosed with primary breast,cervical, endometrial or ovarian cancer (stage I-III)
* Completed initial regional and systemic treatment for breast cancer 2 months ago
* Physically capable of doing the hula-based physical activity
* Receives approval by attending physician to participate in trial

### Exclusion Criteria

* Currently undergoing chemotherapy or radiation therapy

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

